# EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

> **NCT04437368** · PHASE2 · TERMINATED · sponsor: **Gyroscope Therapeutics Limited** · enrollment: 98 (actual)

## Conditions studied

- Dry Age-related Macular Degeneration

## Interventions

- **DRUG:** GT005

## Key facts

- **NCT ID:** NCT04437368
- **Lead sponsor:** Gyroscope Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-26
- **Primary completion:** 2024-04-05
- **Final completion:** 2024-04-05
- **Target enrollment:** 98 (ACTUAL)
- **Why stopped:** Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04437368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04437368, "EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04437368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*